Moreover, Bogen et al. [169] proposed an innovative approach to simultaneously block EGFR and PD-1/PD-L1 signalings, and meanwhile to potentiate NK-mediated ADCC against EGFR+PD-L1+ cancer cells, with a tri-specific anti-EGFR×CD16a×PD-L1 antibody. Here, EGFR is linked to cancer.